Ironwood Pharma (IRWD) Tops Q3 EPS by 2c; Initiates Phase III Trial of 72 mcg Linaclotide

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. MU
4. DPZ
5. ACN
6. NAVN
7. DFTX
8. IBM
9. META
10. ENRD

Go back to Ironwood Pharma (IRWD) Tops Q3 EPS by 2c; Initiates Phase III Trial of 72 mcg Linaclotide

Cantor Fitzgerald Downgrades Ironwood Pharmaceuticals (IRWD) to Sell

November 6, 2014 7:35 AM EST

Cantor Fitzgerald downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Hold to Sell with a price target of $10.00 (from $11.00). Analyst Irina Rivkind Koffler sees downside as sentiment deteriorates.

"We are lowering our PT to $10 from $11 based on DCF valuation since we assume increased R&D expense in 2015. More importantly, we believe that sentiment may turn even more negative if risky clinical programs fail and there is heightened... More